PMID- 35419726
OWN - NLM
STAT- MEDLINE
DCOM- 20221003
LR  - 20240904
IS  - 1993-0402 (Electronic)
IS  - 1672-0415 (Print)
IS  - 1672-0415 (Linking)
VI  - 28
IP  - 10
DP  - 2022 Oct
TI  - Efficacy and Safety of Guihuang Formula in Treating Type III Prostatitis Patients 
      with Dampness-Heat and Blood Stasis Syndrome: A Randomized Controlled Trial.
PG  - 879-884
LID - 10.1007/s11655-022-3467-1 [doi]
AB  - OBJECTIVE: To observe the efficacy and safety of Guihuang Formula (GHF) in 
      treating patients with type III prostatitis and Chinese medicine syndrome of 
      dampness-heat and blood stasis. METHODS: Sixty-six patients diagnosed with type 
      III prostatitis with dampness-heat and blood stasis syndrome were randomly 
      divided into the treatment group (GHF) and the control group (tamsulosin) using a 
      random number table, with 33 cases each group. The treatment group received GHF 
      twice a day, and the control group received tamsulosin 0.2 mg once daily before 
      bedtime. Patients in both groups received treatment for 6 weeks and was followed 
      up for 2 weeks. The outcomes included the National Institute of Health Chronic 
      Prostatitis Symptom Index (NIH-CPSI) score, Chinese Medicine Symptoms Score 
      (CMSS), expressed prostatic secretions (EPS) and adverse events (AEs). RESULTS: 
      After treatment, the NIH-CPSI total score and domain scores of pain discomfort, 
      urination and quality of life decreased significantly from the baseline in both 
      groups (P<0.05). The CMSS score decreased in both groups (P<0.05). The WBC count 
      decreased and lecithin body count increased in both groups (P<0.05). GHF showed a 
      more obvious advantage in reducing the pain discomfort and quality of life domain 
      scores of NIH-CPSI, reducing the CMSS score, increasing the improvement rate of 
      the WBC and lecithin body counts, compared with the control group (P<0.05). There 
      were no significant differences in decreasing urination domain score of NIH-CPSI 
      between two groups (P>0.05). In addition, no serious AEs were observed. 
      CONCLUSION: GHF is effective in treating type III prostatitis patients with 
      dampness-heat and blood stasis syndrome without serious AEs. (Registration No. 
      ChiCTR1900026966).
CI  - (c) 2022. The Chinese Journal of Integrated Traditional and Western Medicine Press 
      and Springer-Verlag GmbH Germany, part of Springer Nature.
FAU - Liu, Sheng-Jing
AU  - Liu SJ
AD  - Department of Andrology, Xiyuan Hospital of China Academy of Chinese Medical 
      Sciences, Beijing, 100091, China.
AD  - Graduate School of China Academy of Chinese Medical Sciences, Beijing, 100700, 
      China.
FAU - Deng, Ying-Jun
AU  - Deng YJ
AD  - Department of Andrology, Xiyuan Hospital of China Academy of Chinese Medical 
      Sciences, Beijing, 100091, China.
FAU - Zeng, Yin
AU  - Zeng Y
AD  - Department of Andrology, Beijing Chinese Medicine Hospital Affiliated to Capital 
      Medical University, Beijing, 100010, China.
FAU - Zhao, Ming
AU  - Zhao M
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, 100029, China.
FAU - Guo, Jun
AU  - Guo J
AD  - Department of Andrology, Xiyuan Hospital of China Academy of Chinese Medical 
      Sciences, Beijing, 100091, China.
FAU - Gao, Qing-He
AU  - Gao QH
AD  - Department of Andrology, Xiyuan Hospital of China Academy of Chinese Medical 
      Sciences, Beijing, 100091, China. gaoqinghe1949@126.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220413
PL  - China
TA  - Chin J Integr Med
JT  - Chinese journal of integrative medicine
JID - 101181180
RN  - 0 (Lecithins)
RN  - G3P28OML5I (Tamsulosin)
SB  - IM
MH  - Chronic Disease
MH  - Hot Temperature
MH  - Humans
MH  - Lecithins
MH  - Male
MH  - Pain
MH  - *Prostatitis/drug therapy
MH  - Quality of Life
MH  - Tamsulosin
PMC - PMC9007251
OTO - NOTNLM
OT  - Chinese medicine
OT  - Guihuang Formula
OT  - dampness-heat and blood stasis syndrome
OT  - randomized controlled trial
OT  - type III prostatitis
EDAT- 2022/04/15 06:00
MHDA- 2022/10/04 06:00
PMCR- 2022/04/13
CRDT- 2022/04/14 05:23
PHST- 2021/11/17 00:00 [accepted]
PHST- 2022/04/15 06:00 [pubmed]
PHST- 2022/10/04 06:00 [medline]
PHST- 2022/04/14 05:23 [entrez]
PHST- 2022/04/13 00:00 [pmc-release]
AID - 10.1007/s11655-022-3467-1 [pii]
AID - 3467 [pii]
AID - 10.1007/s11655-022-3467-1 [doi]
PST - ppublish
SO  - Chin J Integr Med. 2022 Oct;28(10):879-884. doi: 10.1007/s11655-022-3467-1. Epub 
      2022 Apr 13.